Eli Lilly halted development of an unnamed GLP-1 weight-loss drug candidate after it fell short of the company’s efficacy expectations. In the second quarter of 2026, Mounjaro, Zepbound and its new pill Foundayo together accounted for just over 65% of revenue.
The article says Lilly is using proceeds from its GLP-1 drugs to fund internal research and acquisitions. Three deals announced in one day expanded the company into infectious diseases; since announcing that move in May, Lilly has announced two more acquisitions.
The article links diversification to limited patent protection, saying generic competition will eventually reduce GLP-1 revenue. It does not name the discontinued candidate or provide efficacy figures.
